Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Alpha Cognition Inc. (V:ACOG)

Business Focus: Biotechnology & Medical Research (NEC)

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEDI filings for ACOG within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Oct 31, 2024 08:30 ET
Alpha Cognition Announces Proposed Financing and Share Consolidation in connection with Nasdaq Uplisting
Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), is pleased to announce that it has filed a registration statement on Form S-1 (the “Registration Statement”) with the U.S. Securities and Exchange Commission relating to a firm commitment public offering of common shares and pre-funded warrants (collectively, the “Securities”) for gross proceeds of approximately US$25 million (the “Offering”). The Offering is being conducted in conjunction with an application to uplist the Company’s common shares on the Nasdaq Capital Market (“Nasdaq”).
Read full article
Oct 21, 2024 08:30 ET
Alpha Cognition Announces Appointment of VP Finance and Accounting
Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition” or the “Company”), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, announces that Henry Du has joined Alpha Cognition as the VP of Finance and Accounting and interim Chief Financial Officer (CFO).
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
3.29
--
--
Price to Sales - TTM
--
5.13
3.26
Price to Book - most recent quarter
--
2.64
2.11
Price to Cash Flow per share - TTM
--
3.42
11.92
Price to Free Cash Flow per share - TTM
--
14.00
15.47
See all valuations

Short Report

Date Number of Shares Shorted Net Change
Dec 31, 1969 0 0
Dec 31, 1969 0 0
Dec 31, 1969 0 0
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company's pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company's ALPHA-1062 is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer's dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. It is in preclinical development for the treatment of ALS.

See business summary

 

Twitter

Search (past week) for $ACOG.CA ACOG.V

  • No tweets found